Literature DB >> 33854047

TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses.

Nicoletta Caronni1,2, Giulia Maria Piperno3, Francesca Simoncello3, Oriana Romano4, Simone Vodret5, Yuichi Yanagihashi6, Regine Dress7, Charles-Antoine Dutertre7, Mattia Bugatti8, Pierre Bourdeley9, Annalisa Del Prete10,11, Tiziana Schioppa10,11, Emilia Maria Cristina Mazza4,12, Licio Collavin13, Serena Zacchigna5,14, Renato Ostuni15,16, Pierre Guermonprez9, William Vermi8,17, Florent Ginhoux7,18,19, Silvio Bicciato4, Shigekatzu Nagata6, Federica Benvenuti20.   

Abstract

Acquisition of cell-associated tumor antigens by type 1 dendritic cells (cDC1) is essential to induce and sustain tumor specific CD8+ T cells via cross-presentation. Here we show that capture and engulfment of cell associated antigens by tissue resident lung cDC1 is inhibited during progression of mouse lung tumors. Mechanistically, loss of phagocytosis is linked to tumor-mediated downregulation of the phosphatidylserine receptor TIM4, that is highly expressed in normal lung resident cDC1. TIM4 receptor blockade and conditional cDC1 deletion impair activation of tumor specific CD8+ T cells and promote tumor progression. In human lung adenocarcinomas, TIM4 transcripts increase the prognostic value of a cDC1 signature and predict responses to PD-1 treatment. Thus, TIM4 on lung resident cDC1 contributes to immune surveillance and its expression is suppressed in advanced tumors.

Entities:  

Year:  2021        PMID: 33854047     DOI: 10.1038/s41467-021-22535-z

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  58 in total

1.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

Authors:  Miranda L Broz; Mikhail Binnewies; Bijan Boldajipour; Amanda E Nelson; Joshua L Pollack; David J Erle; Andrea Barczak; Michael D Rosenblum; Adil Daud; Diane L Barber; Sebastian Amigorena; Laura J Van't Veer; Anne I Sperling; Denise M Wolf; Matthew F Krummel
Journal:  Cancer Cell       Date:  2014-10-16       Impact factor: 31.743

2.  The identification of some human metabolites of norgestrel, a new progestational agent.

Authors:  D C DeJongh; J D Hribar; P Littleton; K Fotherby; R W Rees; S Shrader; T J Foell; H Smith
Journal:  Steroids       Date:  1968-05       Impact factor: 2.668

3.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

Authors:  Brian Ruffell; Debbie Chang-Strachan; Vivien Chan; Alexander Rosenbusch; Christine M T Ho; Nancy Pryer; Dylan Daniel; E Shelley Hwang; Hope S Rugo; Lisa M Coussens
Journal:  Cancer Cell       Date:  2014-10-16       Impact factor: 31.743

4.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Authors:  Seng-Ryong Woo; Mercedes B Fuertes; Leticia Corrales; Stefani Spranger; Michael J Furdyna; Michael Y K Leung; Ryan Duggan; Ying Wang; Glen N Barber; Katherine A Fitzgerald; Maria-Luisa Alegre; Thomas F Gajewski
Journal:  Immunity       Date:  2014-11-05       Impact factor: 31.745

5.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Authors:  Hélène Salmon; Juliana Idoyaga; Adeeb Rahman; Marylène Leboeuf; Romain Remark; Stefan Jordan; Maria Casanova-Acebes; Makhzuna Khudoynazarova; Judith Agudo; Navpreet Tung; Svetoslav Chakarov; Christina Rivera; Brandon Hogstad; Marcus Bosenberg; Daigo Hashimoto; Sacha Gnjatic; Nina Bhardwaj; Anna Karolina Palucka; Brian D Brown; Joshua Brody; Florent Ginhoux; Miriam Merad
Journal:  Immunity       Date:  2016-04-19       Impact factor: 31.745

6.  ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.

Authors:  Juan R Cubillos-Ruiz; Pedro C Silberman; Melanie R Rutkowski; Sahil Chopra; Alfredo Perales-Puchalt; Minkyung Song; Sheng Zhang; Sarah E Bettigole; Divya Gupta; Kevin Holcomb; Lora H Ellenson; Thomas Caputo; Ann-Hwee Lee; Jose R Conejo-Garcia; Laurie H Glimcher
Journal:  Cell       Date:  2015-06-11       Impact factor: 41.582

7.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

8.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.

Authors:  Jan P Böttcher; Eduardo Bonavita; Probir Chakravarty; Hanna Blees; Mar Cabeza-Cabrerizo; Stefano Sammicheli; Neil C Rogers; Erik Sahai; Santiago Zelenay; Caetano Reis e Sousa
Journal:  Cell       Date:  2018-02-08       Impact factor: 41.582

9.  Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Authors:  Kai Hildner; Brian T Edelson; Whitney E Purtha; Mark Diamond; Hirokazu Matsushita; Masako Kohyama; Boris Calderon; Barbara U Schraml; Emil R Unanue; Michael S Diamond; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy
Journal:  Science       Date:  2008-11-14       Impact factor: 47.728

10.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

Authors:  Alfonso R Sánchez-Paulete; Francisco J Cueto; María Martínez-López; Sara Labiano; Aizea Morales-Kastresana; María E Rodríguez-Ruiz; Maria Jure-Kunkel; Arantza Azpilikueta; M Angela Aznar; José I Quetglas; David Sancho; Ignacio Melero
Journal:  Cancer Discov       Date:  2015-10-22       Impact factor: 39.397

View more
  5 in total

1.  Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy.

Authors:  Diana Corogeanu; Sandra S Diebold
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

2.  Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade.

Authors:  Haoxiao Zuo; Marie-José C van Lierop; Jorn Kaspers; Remco Bos; Anneke Reurs; Saheli Sarkar; Tania Konry; Alwin Kamermans; Gijs Kooij; Helga E de Vries; Tanja D de Gruijl; Alex Karlsson-Parra; Erik H Manting; Ada M Kruisbeek; Satwinder Kaur Singh
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

3.  Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression.

Authors:  María Luisa Molina; David García-Bernal; María Dolores Salinas; Gonzalo Rubio; Pedro Aparicio; José M Moraleda; Salvador Martínez; Rut Valdor
Journal:  Front Cell Dev Biol       Date:  2022-03-18

Review 4.  Centrality of Myeloid-Lineage Phagocytes in Particle-Triggered Inflammation and Autoimmunity.

Authors:  Olivia K Favor; James J Pestka; Melissa A Bates; Kin Sing Stephen Lee
Journal:  Front Toxicol       Date:  2021-11-04

5.  CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors.

Authors:  Francesca Simoncello; Giulia Maria Piperno; Nicoletta Caronni; Roberto Amadio; Ambra Cappelletto; Giulia Canarutto; Silvano Piazza; Silvio Bicciato; Federica Benvenuti
Journal:  Oncoimmunology       Date:  2022-04-07       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.